Decitabine Plus Penpulimab as Second-line Therapy for Advanced ESCC Treated With PD-1 Blockade
- Status
- UNKNOWN
- Phase
- PHASE2
Clinical Trials Related to Esophageal Squamous Cell Carcinoma
Related studies linked through entity extraction aliases.
Anlotinib Hydrochloride Capsules Combined With TQB2450 Injection in Esophageal Squamous Cell Carcinoma Patients
- Status
- RECRUITING
- Phase
- PHASE2
Sintilimab Plus NCT or NCRT Versus NCRT for ESCC
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE3
Study of Neoadjuvant Nivolumab or Placebo Plus Chemotherapy Followed by Surgery and Adjuvant Treatment in Subjects With Resectable ESCC
- Status
- UNKNOWN
- Phase
- PHASE2/PHASE3
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1
Correlation Between the Efficacy of Neoadjuvant Chemotherapy Combined With Immunotherapy of Operable Thoracic Esophageal Squamous Cell Carcinoma and the Metabolites of Intestinal Flora
- Status
- UNKNOWN
- Phase
- NA
Selected Chemotherapy Combined Immunotherapy Treated High Risk Patient After NCRT in Resected Locally Advanced ESCC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Effectiveness of Neoadjuvant Chemotherapy Combined With PD-1 Monoclonal Antibody in the Treatment of Operable Esophageal Squamous Cell Carcinoma
- Status
- UNKNOWN
- Phase
- PHASE2
Trastuzumab and Standard Treatment With Chemo- and Immunotherapy as First Line Treatment for HER2 Positive Esophageal Squamous Cell Carcinoma Patients
- Status
- UNKNOWN
- Phase
- PHASE2
RAPA-201 Therapy of Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Exploration of Immunodynamic Monitoring in the Population Evaluation of Neoadjuvant Chemotherapy Immunotherapy in Patients With Solid Tumors of the Chest.
- Status
- UNKNOWN
- Phase
- PHASE2
Anlotinib Combined With TQB2450 (PD-L1 Inhibitor) in the Treatment of Advanced Esophageal Squamous Cell Carcinoma(ESCC)
- Status
- UNKNOWN
- Phase
- PHASE2
Novel Strategy for Early Detection of Esophageal Squamous Cell Carcinoma
- Status
- RECRUITING
- Phase
- NA
Neoadjuvant Immunotherapy (PD-1 / PD-L1) Combined With Chemotherapy for Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma: a Single Center, Prospective, Open, One Arm Exploratory Clinical Study
- Status
- UNKNOWN
- Phase
- N/A
PD-1 Inhibitor Combined With Neoadjuvant Chemotherapy in Subjects With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma
- Status
- UNKNOWN
- Phase
- PHASE2
Chidamide Plus Camrelizumab as Second-line Therapy for Advanced ESCC Treated With PD-1 Blockade
- Status
- UNKNOWN
- Phase
- PHASE2
A Study of Participants With Squamous Cell Oesophageal Carcinoma Receiving Nivolumab as Part of an Early Access to Medicines Scheme (EAMS) Program in the United Kingdom
- Status
- COMPLETED
- Phase
- N/A
Chemoradiation and Pembrolizumab Followed by Pembrolizumab and Lenvatinib Before Surgery for the Treatment of Non-metastatic Esophageal or Esophageal/Gastroesophageal Junction Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Afatinib Plus Toripalimab in Previously Treated ESCC With EGFR Overexpression or EGFR Amplification
- Status
- UNKNOWN
- Phase
- PHASE2